Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MPO | P05164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375388 | 0.76 | TP53 (0.46) | MAPTKDM4EKMT2AALDH1A1TP53 | |
| SCHEMBL27688040 | 0.72 | RAD52 (0.77) | MAPTKDM4ESMN1; SMN2MPOMAPK1 | |
| SCHEMBL7677878 | 0.70 | GRM2 (0.43) | MPOKMT2AALDH1A1TP53RAB9A | |
| SCHEMBL4310110 | 0.67 | MAPT (0.58) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL4310107 | 0.67 | MAPT (0.58) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL4161901 | 0.62 | LMNA (0.53) | SMN1; SMN2KMT2AALDH1A1RAB9APOLB | |
| SCHEMBL8207778 | 0.62 | ALDH1A1 (0.57) | SMN1; SMN2KMT2AALDH1A1RAB9APOLB | |
| SCHEMBL10308967 | 0.62 | GRM2 (0.50) | MAPTKDM4ESMN1; SMN2MPOKMT2A | |
| SCHEMBL4095314 | 0.60 | KMT2A (0.66) | MAPTKDM4ESMN1; SMN2KMT2AHPGD | |
| SCHEMBL4095316 | 0.60 | KMT2A (0.66) | MAPTKDM4ESMN1; SMN2KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073611-A1 | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2003-04-17 | — | — | US | claimed |
| WO-2002076439-A2 | COMPOUNDS CAPABLE OF MODULATING THE ACTIVITY OF MULTIDRUG TRANSPORTERS AND THERAPEUTIC USE OF THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-10-03 | — | — | WO | claimed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-2066331-A2 | METHODS FOR TREATING PAIN WITH REDUCED NUASEA AND VOMITING | Limerick BioPharma, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090088394-A1 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | ROBBINS WENDYE | 2009-04-02 | — | — | US | disclosed |
| US-20090076053-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | EFFLUX TECHNOLOGY, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2008070346-A9 | METHODS FOR TREATING PAIN WITH REDUCED NUASEA AND VOMITING | LIMERICK BIOPHARMA INC (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080161248-A1 | Methods and Compositions for Therapeutic Treatment | LIMERICK BIOPHARMA, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008070346-A2 | METHODS FOR TREATING PAIN WITH REDUCED NUASEA AND VOMITING | LIMERICK BIOPHARMA, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070087977-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | LIMERICK BIOPHARMA, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20060111307-A1 | Methods and compositions for treating pain | LIMERICK NEUROSCIENCES, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060111308-A1 | Methods and compositions for therapeutic treatment | LIMERICK NEUROSCIENCES, INC. | 2006-05-25 | — | — | US | disclosed |
| US-6861431-B2 | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111307-A1 | Methods and compositions for treating pain | PGF, FABP7, ALPP | MAPT 911/4885KDM4E 4712/4885SMN1; SMN2 772/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | MAPT 2244/4885KDM4E 4285/4885SMN1; SMN2 4592/4885 |
| US-20070087977-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | PGF, FABP7, ALPP | MAPT 911/4885KDM4E 4712/4885SMN1; SMN2 772/4885 |
| US-20030073611-A1 | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same | ABCB1, SLC47A1, SLC47A2 | MAPT 2208/4885KDM4E 3995/4885SMN1; SMN2 4267/4885 |
| US-20090088394-A1 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | PGF, FABP7, ALPP | MAPT 895/4885KDM4E 4598/4885SMN1; SMN2 1243/4885 |
| US-20090076053-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | PGF, FABP7, ALPP | MAPT 911/4885KDM4E 4712/4885SMN1; SMN2 772/4885 |
| US-20060111308-A1 | Methods and compositions for therapeutic treatment | PGF, FABP7, ALPP | MAPT 895/4885KDM4E 4598/4885SMN1; SMN2 1243/4885 |
| US-20080161248-A1 | Methods and Compositions for Therapeutic Treatment | PGF, ALPP, CHP1 | MAPT 1103/4885KDM4E 4212/4885SMN1; SMN2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.